Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Mephedrone hydrochlorideCat. No. 4443 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (±)-2-Methylamino-1-(4-methylphenyl)propan-1-one hydrochloride |
Biological Activity
Inhibits striatal dopamine uptake and hippocampal 5-HT uptake in synaptosomes (IC50 values are 467 and 558 nM respectively). Administration causes a decrease in dopamine and 5-HT transporter function. Synthetic CNS stimulant; brain penetrant.Certificate of Analysis / Safety Data Sheet
Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet
References
Hadlock et al (2011) 4-methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J.Pharmacol.Exp.Ther. 339 530. PMID: 21810934.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Mephedrone hydrochloride, supplier, inhibitors, inhibits, dopamine, da, 5-ht, serotonin, uptake, transporters, brain, penetrant
Quick Order
Find multiple products by catalog number
New Products in this Area
Org 25543 hydrochloride
Potent and selective GlyT2 inhibitor
Escitalopram oxalateSelective serotonin reuptake inhibitor (SSRI)
(S)-Duloxetine hydrochloridePotent 5-HT and NE reuptake inhibitor; also blocks dopamine reuptake
Decynium 22PMAT inhibitor
Sign-up for new product e-alerts
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.




